4-(4-n-butyl-4-methoxy-piperidin-1-yl)-benzoic acid ethyl ester | 810686-37-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-n-butyl-4-methoxy-piperidin-1-yl)-benzoic acid ethyl ester
• 英文别名: ethyl 4-(4-butyl-4-methoxy-1-piperidyl)benzoate；ethyl 4-(4-butyl-4-methoxypiperidin-1-yl)benzoate
• CAS: 810686-37-4
• 化学式: C₁₉H₂₉NO₃
• 分子量: 319.444
• InChiKey: WKVDRQUOSSUXQM-UHFFFAOYSA-N

物化性质

• 沸点：
  434.2±40.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-n-butyl-4-methoxy-piperidin-1-yl)-benzoic acid ethyl ester 在 肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 7.0h， 生成 4-(4-butyl-4-methoxy-1-piperidyl)benzohydrazide
  参考文献：
  名称：

  New compound

  摘要：

  本发明涉及一种由以下一般式（I）表示的新脂肽化合物：其中R1、R2、R3、R4和R5如描述中所定义，或其盐，具有抗微生物活性（特别是抗真菌活性），对β-1,3-葡聚糖合酶的抑制活性，制备过程，包含该化合物的药物组合物，以及预防和/或治疗包括肺孢子虫感染（例如肺孢子虫性肺炎）在人类或动物中的传染病的方法。

  公开号：

  US20050004014A1
• 作为产物：
  描述：

  4-(4-氧代哌啶-1-基)苯甲酸乙酯 在 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 2.0h， 生成 4-(4-n-butyl-4-methoxy-piperidin-1-yl)-benzoic acid ethyl ester
  参考文献：
  名称：

  Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL

  摘要：

  Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy. Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy. We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation. Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2. This study culminated in the identification of 2, which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, respectively. Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.

  DOI：

  10.1021/jm061152t

文献信息

• [EN] CYCLIC LIPOPEPTIDES<br/>[FR] LIPOPEPTIDES CYCLIQUES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004113368A1

  公开（公告）日：2004-12-29

  This invention relates to new lipopeptide compound represented by the following general formula (I): wherein R1, R2, R3, R4 and R5 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on (3-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
• Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
  作者：Milan Bruncko、Thorsten K. Oost、Barbara A. Belli、Hong Ding、Mary K. Joseph、Aaron Kunzer、Darlene Martineau、William J. McClellan、Michael Mitten、Shi-Chung Ng、Paul M. Nimmer、Tilman Oltersdorf、Cheol-Min Park、Andrew M. Petros、Alexander R. Shoemaker、Xiaohong Song、Xilu Wang、Michael D. Wendt、Haichao Zhang、Stephen W. Fesik、Saul H. Rosenberg、Steven W. Elmore

  DOI：10.1021/jm061152t

  日期：2007.2.1

  Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy. Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy. We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation. Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2. This study culminated in the identification of 2, which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, respectively. Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.
• New compound
  申请人：Matsuya Takahiro

  公开号：US20050004014A1

  公开（公告）日：2005-01-06

  This invention relates to new lipopeptide compound represented by the following general formula (I): wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

  本发明涉及一种由以下一般式（I）表示的新脂肽化合物：其中R1、R2、R3、R4和R5如描述中所定义，或其盐，具有抗微生物活性（特别是抗真菌活性），对β-1,3-葡聚糖合酶的抑制活性，制备过程，包含该化合物的药物组合物，以及预防和/或治疗包括肺孢子虫感染（例如肺孢子虫性肺炎）在人类或动物中的传染病的方法。